UPDATE: Canaccord Raises Target to $22 on Inhibitex
Canaccord maintains its Buy rating on Inhibitex, Inc. (NASDAQ: INHX) and raises its price target to $22 as INX-189/ribavirin synergy supports nuc potency.
Cannaccord says, “Informed by solid combo 7-day treatment data, our outlook on lead HCV nuc prodrug INX-189 has vastly improved. Multiple catalysts should drive stock momentum into 2012. We maintain our BUY and increase our price target to $22 from $15.”
INHX closed at $13.70 per share on Tuesday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.